Key clinical point: No significant differences in prostate specific antigen PSA regression, PSA failure rate, and toxicity were noted between the different fraction schedules for patients treated with high-dose-rate mono-brachytherapy.
Major finding: Overall, the biochemical failure rate was 9.6%; biochemical failure rates for the 4F, 3F, and 2F groups 10.5%, 4.7%, and 14.6%, respectively, and 3.5% of patients demonstrated several grade 3-4 toxicity.
Study details: The data come from a retrospective study of 229 adults with prostate cancer treated consecutively at a single center between 2004 and 2012. Patients were treated with high-dose-rate mono-brachytherapy alone, using three different fractionation schedules of 92-95 Gy.
Group 4F had a single implant of 9.5 Gy in four fractions over 2 days. Group 3F had three separate implants of 11 Gy over 4 weeks. Group had two implants of 14 Gy over 2 weeks.
Disclosures: The study was funded by the Örebro County Council. The researchers had no financial conflicts to disclose.
Source: Johansson B et al. J Contemp Brachytherapy. 2021 May 5. doi: 10.5114/jcb.2021.105846.